[尽管出现与治疗相关的范科尼综合征和骨软化症，但仍继续使用阿德福韦酯治疗的1例慢性乙型肝炎病例]

[A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia].

作者信息

Iizuka Yasuhiro, Sakai Hideki, Kobayashi Konomi, Iizuka Kazue, Ito Eri, Mochizuki Nahoko, Asahina Yasuhiro, Watanabe Mamoru

机构信息

Department of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital.

出版信息

Nihon Shokakibyo Gakkai Zasshi. 2014 Aug;111(8):1618-23.

PMID:25100352

Abstract

A 64-year-old woman was prescribed lamivudine and adefovir (ADV) for chronic hepatitis B. Although her serum creatinine level was normal (<1.01 mg/dl), she developed bone pain due to Fanconi syndrome and osteomalacia. Therefore, ADV was discontinued and she was switched to entecavir (ETV); however, she developed an ETV-resistant mutant virus and a small dose of ADV was restarted. Her hepatitis B virus (HBV) -DNA levels and renal function were closely monitored. She has had preserved creatinine levels and tubular function, with almost undetectable HBV-DNA levels for more than a year after treatment.

摘要

一名64岁女性因慢性乙型肝炎接受拉米夫定和阿德福韦（ADV）治疗。尽管她的血清肌酐水平正常（<1.01 mg/dl），但她因范科尼综合征和骨软化症出现了骨痛。因此，停用了ADV，转而使用恩替卡韦（ETV）；然而，她出现了对ETV耐药的突变病毒，于是重新开始使用小剂量的ADV。密切监测她的乙型肝炎病毒（HBV）-DNA水平和肾功能。治疗后一年多来，她的肌酐水平和肾小管功能保持良好，HBV-DNA水平几乎检测不到。